Base de dados : MEDLINE
Pesquisa : C23.550.568.500 [Categoria DeCS]
Referências encontradas : 8323 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 833 ir para página                         

  1 / 8323 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328563
[Au] Autor:Dragovic T; Duran Z; Jelic S; Marinkovic D; Kikovic S; Kuzmic-Jankovic S; Hajdukovic Z
[Ti] Título:Coexisting diseases modifying each other's presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism.
[So] Source:Vojnosanit Pregl;73(10):961-6, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Turner syndrome presents with one of the most frequent chromosomal aberrations in female, typically presented with growth retardation, ovarian insufficiency, facial dysmorphism, and numerous other somatic stigmata. Gigantism is an extremely rare condition resulting from an excessive growth hormone (GH) secretion that occurs during childhood before the fusion of epiphyseal growth plates. The major clinical feature of gigantism is growth acceleration, although these patients also suffer from hypogonadism and soft tissue hypertrophy. Case report: We presented a girl with mosaic Turner syndrome, delayed puberty and normal linear growth for the sex and age, due to the simultaneous GH hypersecretion by pituitary tumor. In the presented case all the typical phenotypic stigmata related to Turner syndrome were missing. Due to excessive pituitary GH secretion during the period while the epiphyseal growth plates of the long bones are still open, characteristic stagnation in longitudinal growth has not been demonstrated. The patient presented with delayed puberty and primary amenorrhea along with a sudden appearance of clinical signs of hypersomatotropinism, which were the reasons for seeking medical help at the age of 16. Conclusion: Physical examination of children presenting with delayed puberty but without growth arrest must include an overall hormonal and genetic testing even in the cases when typical clinical presentations of genetic disorder are absent. To the best of our knowledge, this is the first reported case of simultaneous presence of Turner syndrome and gigantism in the literature.
[Mh] Termos MeSH primário: Adenoma/complicações
Desenvolvimento do Adolescente
Estatura
Gigantismo/etiologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações
Síndrome de Turner/complicações
[Mh] Termos MeSH secundário: Adenoma/sangue
Adenoma/fisiopatologia
Adenoma/cirurgia
Adolescente
Amenorreia/etiologia
Amenorreia/fisiopatologia
Biomarcadores/sangue
Feminino
Gigantismo/sangue
Gigantismo/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Terapia de Reposição Hormonal
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Imagem por Ressonância Magnética
Mosaicismo
Puberdade Tardia/etiologia
Puberdade Tardia/fisiopatologia
Resultado do Tratamento
Síndrome de Turner/tratamento farmacológico
Síndrome de Turner/genética
Síndrome de Turner/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (IGF1 protein, human); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150620014D


  2 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28904704
[Au] Autor:Barka I; Dendana E; Chikhrouhou N; Maroufi A; Kacem M; Chadli M; Ach K
[Ad] Endereço:Service d'Endocrinologie, CHU Farhat Hached de Sousse, Tunisie.
[Ti] Título:[Prolactin-secreting microadenoma in menopausal women].
[Ti] Título:Micro adénome à prolactine à l'âge de la ménopause..
[So] Source:Pan Afr Med J;27:177, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:fre
[Ab] Resumo:Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Physical examination confirmed the diagnosis of galactorrhoea and biology showed hyperprolactinemia at mIU/L, FSH = 15.1 IU/L and LH = 4,1 IU/L. Pituitary MRI showed left adenoma measuring 8 mm. Patient's evolution under dopaminergic treatment was marked by the recovery, for a transitional period, of mestrual cycles and the occurrence of hot flushes, normalization of prolactin levels and reduction of adenoma size.
[Mh] Termos MeSH primário: Adenoma/diagnóstico por imagem
Neoplasias Hipofisárias/diagnóstico por imagem
Prolactina/secreção
Prolactinoma/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adenoma/patologia
Adenoma/terapia
Amenorreia/diagnóstico
Amenorreia/etiologia
Feminino
Galactorreia/diagnóstico
Galactorreia/etiologia
Seres Humanos
Hiperprolactinemia/etiologia
Imagem por Ressonância Magnética
Menopausa
Meia-Idade
Neoplasias Hipofisárias/patologia
Neoplasias Hipofisárias/terapia
Prolactinoma/patologia
Prolactinoma/terapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
9002-62-4 (Prolactin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.177.11677


  3 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28851765
[Au] Autor:Farland LV; Eliassen AH; Tamimi RM; Spiegelman D; Michels KB; Missmer SA
[Ad] Endereço:Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA lfarland@mail.harvard.edu.
[Ti] Título:History of breast feeding and risk of incident endometriosis: prospective cohort study.
[So] Source:BMJ;358:j3778, 2017 Aug 29.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo: To investigate the association between lifetime breast feeding, exclusive breast feeding, postpartum amenorrhea, and incidence of endometriosis among parous women. Prospective cohort study. Nurses' Health Study II, 1989-2011. 72 394women who reported having one or more pregnancies that lasted at least six months, 3296 of whom had laparoscopically confirmed endometriosis. For each pregnancy, women reported duration of total breast feeding, exclusive breast feeding, and postpartum amenorrhea.  Incident self reported laparoscopically confirmed endometriosis (96% concordance with medical record) in parous women. Multivariable Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals for diagnosis of endometriosis. Duration of total and exclusive breast feeding was significantly associated with decreased risk of endometriosis. Among women who reported a lifetime total length of breast feeding of less than one month, there were 453 endometriosis cases/100 000 person years compared with 184 cases/100 000 person years in women who reported a lifetime total of ≥36 months of breast feeding. For every additional three months of total breast feeding per pregnancy, women experienced an 8% lower risk of endometriosis (hazard ratio 0.92, 95% confidence interval 0.90 to 0.94; P<0.001 for trend) and a 14% lower risk for every additional three months of exclusive breast feeding per pregnancy (0.86, 0.81 to 0.90; P<0.001 for trend). Women who breastfed for ≥36 months in total across their reproductive lifetime had a 40% reduced risk of endometriosis compared with women who never breast fed (0.60, 0.50 to 0.72). The protective association with breast feeding was strongest among women who gave birth within the past five years (P=0.04 for interaction). The association with total breast feeding and exclusive breast feeding on endometriosis was partially influenced by postpartum amenorrhea (% mediated was 34% (95% confidence interval 15% to 59%) for total breast feeding and 57% (27% to 82%) for exclusive breast feeding). Among women who experienced at least one pregnancy that lasted at least six months, breast feeding was inversely associated with risk of incident endometriosis. This association was partially, but not fully, influenced by postpartum amenorrhea, suggesting that breast feeding could influence the risk of endometriosis both through amenorrhea and other mechanisms. Given the chronic and incurable nature of endometriosis, breast feeding should be further investigated as an important modifiable behavior to mitigate risk for pregnant women.
[Mh] Termos MeSH primário: Aleitamento Materno
Endometriose/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Amenorreia/epidemiologia
Endometriose/diagnóstico por imagem
Endometriose/cirurgia
Feminino
Seguimentos
Seres Humanos
Incidência
Laparoscopia
Análise Multivariada
Enfermeiras e Enfermeiros
Modelos de Riscos Proporcionais
Estudos Prospectivos
Risco
Autorrelato
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170831
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j3778


  4 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28669481
[Au] Autor:Böttcher B; Seeber B; Leyendecker G; Wildt L
[Ad] Endereço:Department of Gynecological Endocrinology and Reproductive Medicine, Medical University Innsbruck, Innsbruck, Austria.
[Ti] Título:Impact of the opioid system on the reproductive axis.
[So] Source:Fertil Steril;108(2):207-213, 2017 Aug.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endogenous opioids, first described more than 40 years ago, have long been recognized for their main role as important neuromodulators within the central nervous system. More recently endogenous opioids and their receptor have been identified in a variety of reproductive and nonreproductive tissues outside the central nervous system. Their role within these tissues and organs, however, is only incompletely understood. In the central nervous system, endogenous opioids inhibit pulsatile GnRH release, in part mediating the stress response within the central nervous-pituitary gonadal axis, resulting in hypothalamic amenorrhea. In the ovary, the presence of endogenous opioids primarily produced by granulosa cells has been demonstrated within the follicular fluid, likely influencing oocyte maturation. In hypothalamic amenorrhea, normal cycles can be restored by the administration of opioid antagonists, such as naltrexone. In polycystic ovarian syndrome, endogenous opioids have found to be elevated and may stimulate insulin secretion from the endocrine pancreas. This effect can be inhibited by opioid antagonists, resulting in a decrease of circulating insulin levels in response to glucose challenge. Endogenous opioids may also play a role in the pathogenesis of ovarian hyperstimulation syndrome. In summary, endogenous opioids exert a wide variety of actions within the reproductive system and are worthy of further scientific study.
[Mh] Termos MeSH primário: Amenorreia/metabolismo
Analgésicos Opioides/metabolismo
Hormônios Esteroides Gonadais/metabolismo
Síndrome de Hiperestimulação Ovariana/metabolismo
Ovário/metabolismo
Gravidez/metabolismo
Reprodução/fisiologia
[Mh] Termos MeSH secundário: Animais
Feminino
Seres Humanos
Modelos Biológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Gonadal Steroid Hormones)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE


  5 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28617060
[Au] Autor:Nelson AL
[Ad] Endereço:a Obstetrics & Gynecology, College of Osteopathic Medicine of the Pacific , Western University of Health Sciences , Pomona , CA , USA.
[Ti] Título:Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
[So] Source:Expert Rev Clin Pharmacol;10(8):833-842, 2017 Aug.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of action as well as the results of the Phase II and III clinical trials of its efficacy, safety and tolerability. Expert Commentary: This new LNG-IUS 12 provides five-year contraceptive protection a pregnancy rate (less than 1%) in first year of use, which puts it into the top tier with the existing LNG-IUS 20 products; however, the LNG-IUS 12 does not have the high rates of amenorrhea often seen with the higher dose devices. On the other hand, this new IUD shares the smaller frame and narrower insertion tube with the lower dose LNG-IUS 8, but offers longer effective life.
[Mh] Termos MeSH primário: Anticoncepcionais Femininos/administração & dosagem
Dispositivos Intrauterinos Medicados
Levanogestrel/administração & dosagem
[Mh] Termos MeSH secundário: Amenorreia/epidemiologia
Anticoncepcionais Femininos/efeitos adversos
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Dispositivos Intrauterinos Medicados/efeitos adversos
Levanogestrel/efeitos adversos
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Contraceptive Agents, Female); 5W7SIA7YZW (Levonorgestrel)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170616
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2017.1341308


  6 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28502826
[Au] Autor:Luke AM; Moroney JW; Snitchler A; Whiteway SL
[Ad] Endereço:San Antonio Uniformed Services Health Education Consortium, JBSA, Fort Sam Houston, San Antonio, Texas.
[Ti] Título:Ovarian Sertoli-Leydig Cell Tumor with Elevated Inhibin B as a Cause of Secondary Amenorrhea in an Adolescent with Germ Line DICER1 Mutation.
[So] Source:J Pediatr Adolesc Gynecol;30(5):598-600, 2017 Oct.
[Is] ISSN:1873-4332
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ovarian tumors, although uncommon in children, can retain endocrine function that disrupts normal feedback mechanisms leading to amenorrhea. Inheritance of germline DICER1 mutations can lead to increased risk for development of ovarian Sertoli-Leydig cell tumors (SLCTs). CASE: We report, to our knowledge, the first case of secondary amenorrhea due to elevated inhibin B levels in a female adolescent with an ovarian SLCT. SUMMARY AND CONCLUSION: Ovarian tumors should be included in the differential diagnosis for pediatric patients who present with menstrual irregularities. Early evaluation of the hypothalamic-pituitary-ovarian axis and inhibin levels is appropriate. Our case also emphasizes the need for testing for DICER1 mutations in pediatric patients with ovarian SLCTs.
[Mh] Termos MeSH primário: Amenorreia/etiologia
RNA Helicases DEAD-box/genética
Inibinas/sangue
Neoplasias Ovarianas/patologia
Ribonuclease III/genética
Tumor de Células de Sertoli-Leydig/complicações
[Mh] Termos MeSH secundário: Adolescente
Diagnóstico Diferencial
Feminino
Seres Humanos
Mutação
Neoplasias Ovarianas/complicações
Neoplasias Ovarianas/genética
Tumor de Células de Sertoli-Leydig/genética
Tumor de Células de Sertoli-Leydig/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (inhibin B); 57285-09-3 (Inhibins); EC 3.1.26.3 (DICER1 protein, human); EC 3.1.26.3 (Ribonuclease III); EC 3.6.4.13 (DEAD-box RNA Helicases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE


  7 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28444736
[Au] Autor:Murji A; Whitaker L; Chow TL; Sobel ML
[Ad] Endereço:Department of Obstetrics and Gynecology, Mount Sinai Hospital, University of Toronto, 700 University Ave - 3rd Floor, Toronto, ON, Canada, M5G 1Z5.
[Ti] Título:Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
[So] Source:Cochrane Database Syst Rev;4:CD010770, 2017 Apr 26.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Uterine fibroids are smooth muscle tumours arising from the uterus. These tumours, although benign, are commonly associated with abnormal uterine bleeding, bulk symptoms and reproductive dysfunction. The importance of progesterone in fibroid pathogenesis supports selective progesterone receptor modulators (SPRMs) as effective treatment. Both biochemical and clinical evidence suggests that SPRMs may reduce fibroid growth and ameliorate symptoms. SPRMs can cause unique histological changes to the endometrium that are not related to cancer, are not precancerous and have been found to be benign and reversible. This review summarises randomised trials conducted to evaluate the effectiveness of SPRMs as a class of medication for treatment of individuals with fibroids. OBJECTIVES: To evaluate the effectiveness and safety of SPRMs for treatment of premenopausal women with uterine fibroids. SEARCH METHODS: We searched the Specialised Register of the Cochrane Gynaecology and Fertility Group, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and clinical trials registries from database inception to May 2016. We handsearched the reference lists of relevant articles and contacted experts in the field to request additional data. SELECTION CRITERIA: Included studies were randomised controlled trials (RCTs) of premenopausal women with fibroids who were treated for at least three months with a SPRM. DATA COLLECTION AND ANALYSIS: Two review authors independently reviewed all eligible studies identified by the search. We extracted data and assessed risk of bias independently using standard forms. We analysed data using mean differences (MDs) or standardised mean differences (SMDs) for continuous data and odds ratios (ORs) for dichotomous data. We performed meta-analyses using the random-effects model. Our primary outcome was change in fibroid-related symptoms. MAIN RESULTS: We included in the review 14 RCTs with a total of 1215 study participants. We could not extract complete data from three studies. We included in the meta-analysis 11 studies involving 1021 study participants: 685 received SPRMs and 336 were given a control intervention (placebo or leuprolide). Investigators evaluated three SPRMs: mifepristone (five studies), ulipristal acetate (four studies) and asoprisnil (two studies). The primary outcome was change in fibroid-related symptoms (symptom severity, health-related quality of life, abnormal uterine bleeding, pelvic pain). Adverse event reporting in the included studies was limited to SPRM-associated endometrial changes. More than half (8/14) of these studies were at low risk of bias in all domains. The most common limitation of the other studies was poor reporting of methods. The main limitation for the overall quality of evidence was potential publication bias. SPRM versus placebo SPRM treatment resulted in improvements in fibroid symptom severity (MD -20.04 points, 95% confidence interval (CI) -26.63 to -13.46; four RCTs, 171 women, I = 0%; moderate-quality evidence) and health-related quality of life (MD 22.52 points, 95% CI 12.87 to 32.17; four RCTs, 200 women, I = 63%; moderate-quality evidence) on the Uterine Fibroid Symptom Quality of Life Scale (UFS-QoL, scale 0 to 100). Women treated with an SPRM showed reduced menstrual blood loss on patient-reported bleeding scales, although this effect was small (SMD -1.11, 95% CI -1.38 to -0.83; three RCTs, 310 women, I = 0%; moderate-quality evidence), along with higher rates of amenorrhoea (29 per 1000 in the placebo group vs 237 to 961 per 1000 in the SPRM group; OR 82.50, 95% CI 37.01 to 183.90; seven RCTs, 590 women, I = 0%; moderate-quality evidence), compared with those given placebo. We could draw no conclusions regarding changes in pelvic pain owing to variability in the estimates. With respect to adverse effects, SPRM-associated endometrial changes were more common after SPRM therapy than after placebo (OR 15.12, 95% CI 6.45 to 35.47; five RCTs, 405 women, I = 0%; low-quality evidence). SPRM versus leuprolide acetate In comparing SPRM versus other treatments, two RCTs evaluated SPRM versus leuprolide acetate. One RCT reported primary outcomes. No evidence suggested a difference between SPRM and leuprolide groups for improvement in quality of life, as measured by UFS-QoL fibroid symptom severity scores (MD -3.70 points, 95% CI -9.85 to 2.45; one RCT, 281 women; moderate-quality evidence) and health-related quality of life scores (MD 1.06 points, 95% CI -5.73 to 7.85; one RCT, 281 women; moderate-quality evidence). It was unclear whether results showed a difference between SPRM and leuprolide groups for reduction in menstrual blood loss based on the pictorial blood loss assessment chart (PBAC), as confidence intervals were wide (MD 6 points, 95% CI -40.95 to 50.95; one RCT, 281 women; low-quality evidence), or for rates of amenorrhoea (804 per 1000 in the placebo group vs 732 to 933 per 1000 in the SPRM group; OR 1.14, 95% CI 0.60 to 2.16; one RCT, 280 women; moderate-quality evidence). No evidence revealed differences between groups in pelvic pain scores based on the McGill Pain Questionnaire (scale 0 to 45) (MD -0.01 points, 95% CI -2.14 to 2.12; 281 women; moderate-quality evidence). With respect to adverse effects, SPRM-associated endometrial changes were more common after SPRM therapy than after leuprolide treatment (OR 10.45, 95% CI 5.38 to 20.33; 301 women; moderate-quality evidence). AUTHORS' CONCLUSIONS: Short-term use of SPRMs resulted in improved quality of life, reduced menstrual bleeding and higher rates of amenorrhoea than were seen with placebo. Thus, SPRMs may provide effective treatment for women with symptomatic fibroids. Evidence derived from one RCT showed no difference between leuprolide acetate and SPRM with respect to improved quality of life and bleeding symptoms. Evidence was insufficient to show whether effectiveness was different between SPRMs and leuprolide. Investigators more frequently observed SPRM-associated endometrial changes in women treated with SPRMs than in those treated with placebo or leuprolide acetate. As noted above, SPRM-associated endometrial changes are benign, are not related to cancer and are not precancerous. Reporting bias may impact the conclusion of this meta-analysis. Well-designed RCTs comparing SPRMs versus other treatments are needed.
[Mh] Termos MeSH primário: Antineoplásicos Hormonais/uso terapêutico
Estrenos/uso terapêutico
Leiomioma/tratamento farmacológico
Mifepristona/uso terapêutico
Norpregnadienos/uso terapêutico
Oximas/uso terapêutico
Receptores de Progesterona/antagonistas & inibidores
Neoplasias Uterinas/tratamento farmacológico
[Mh] Termos MeSH secundário: Amenorreia/tratamento farmacológico
Feminino
Seres Humanos
Leuprolida/uso terapêutico
Menstruação/efeitos dos fármacos
Dor Pélvica/tratamento farmacológico
Qualidade de Vida
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents, Hormonal); 0 (Estrenes); 0 (Norpregnadienes); 0 (Oximes); 0 (Receptors, Progesterone); 320T6RNW1F (Mifepristone); 72W09924WP (asoprisnil); EFY6W0M8TG (Leuprolide); YF7V70N02B (ulipristal acetate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD010770.pub2


  8 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28439053
[Au] Autor:Higuchi T
[Ad] Endereço:Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Aomori, Japan.
[Ti] Título:[Calcium and bone metabolism across women's life stages. Bone metabolism of women in primary amenorrhea.]
[So] Source:Clin Calcium;27(5):653-660, 2017.
[Is] ISSN:0917-5857
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:For development of the bone during adolescence, the increased estrogen plays an important role especially in young women as well as GH/IGF-â…  system. Although primary amenorrhea can be caused by various pathological factors, almost of cases have a dysfunction of estrogen secretory systems. For Turner syndrome, which is well-known disease with primary amenorrhea,it is generally recommended that the estrogen therapy is started at adolescence and gradually increased up to adult dose level. Recently studies about the adequate dose of estrogen and the adequate age of adult dose in Turner syndrome revealed that intervention with adult dose of estrogen is required as soon as possible for gaining better bone mineral. In the point of view for bone fragility at the future, early diagnosis and adequate intervention for primary amenorrhea is important.
[Mh] Termos MeSH primário: Amenorreia
Osso e Ossos/metabolismo
Cálcio/metabolismo
[Mh] Termos MeSH secundário: Índice de Massa Corporal
Densidade Óssea
Feminino
Seres Humanos
Puberdade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
SY7Q814VUP (Calcium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:CliCa1705653660


  9 / 8323 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368522
[Au] Autor:Jiao X; Zhang H; Ke H; Zhang J; Cheng L; Liu Y; Qin Y; Chen ZJ
[Ad] Endereço:Center for Reproductive Medicine, Shandong Provincial Hospital Affiliated with Shandong University, Jinan, 250001, Shandong, China.
[Ti] Título:Premature Ovarian Insufficiency: Phenotypic Characterization Within Different Etiologies.
[So] Source:J Clin Endocrinol Metab;102(7):2281-2290, 2017 Jul 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Premature ovarian insufficiency (POI) is highly heterogeneous, both in phenotype and etiology. They are not yet clearly stated and correlated. Objective: To characterize clinical presentations of a large, well-phenotyped cohort of women with POI, and correlate phenotypes with etiologies to draw a comprehensive clinical picture of POI. Design, Patients, Interventions, and Main Outcome Measures: In this retrospective study, a total of 955 Chinese women with overt POI between 2006 and 2015 were systemically evaluated and analyzed. The phenotypic features, including menstrual characteristics, hormone profiles, ovarian ultrasonography/biopsy, pregnancy/family history, and genetic/autoimmune/iatrogenic etiologies were assessed and further compared within different subgroups. Results: Among 955 women with POI, 85.97% presented with secondary amenorrhea (SA) and 14.03% with primary amenorrhea (PA). PA represented the most severe ovarian dysfunction and more chromosomal aberrations than SA. The decline of ovarian function in patients with SA progressed quickly. They had shortened reproductive periods (approximately 10 years) and developed amenorrhea within 1 to 2 years after menstrual irregularity. The ovaries were invisible or small, and the presence of follicles (28.43%) was correlated with other good reproductive indicators. Familial patients (12.25%) manifested better ovarian status and fewer chromosomal aberrations than sporadic patients. The etiologies consisted of genetic (13.15%), autoimmune (12.04%), and iatrogenic (7.29%), approximately 68% remaining idiopathic. There were significant differences among different etiologies, with the genetic group representing the most severe phenotype. Conclusion: Our results regarding distinct phenotypic characteristics and association with different etiologies further confirmed the high heterogeneity of POI. Additional longitudinal clinical studies and pathogenesis research are warranted.
[Mh] Termos MeSH primário: Insuficiência Ovariana Primária/etiologia
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Amenorreia/etiologia
Amenorreia/genética
Autoanticorpos/sangue
Biópsia
Aberrações Cromossômicas
Estudos de Coortes
Feminino
Predisposição Genética para Doença
Seres Humanos
Cariótipo
Mutação
Ovário/diagnóstico por imagem
Ovário/patologia
Ovário/fisiopatologia
Paridade
Fenótipo
Insuficiência Ovariana Primária/diagnóstico por imagem
Insuficiência Ovariana Primária/genética
Insuficiência Ovariana Primária/patologia
História Reprodutiva
Estudos Retrospectivos
Ultrassonografia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Autoantibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2016-3960


  10 / 8323 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368518
[Au] Autor:Gordon CM; Ackerman KE; Berga SL; Kaplan JR; Mastorakos G; Misra M; Murad MH; Santoro NF; Warren MP
[Ad] Endereço:Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229.
[Ti] Título:Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline.
[So] Source:J Clin Endocrinol Metab;102(5):1413-1439, 2017 May 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Cosponsoring Associations: The American Society for Reproductive Medicine, the European Society of Endocrinology, and the Pediatric Endocrine Society. This guideline was funded by the Endocrine Society. Objective: To formulate clinical practice guidelines for the diagnosis and treatment of functional hypothalamic amenorrhea (FHA). Participants: The participants include an Endocrine Society-appointed task force of eight experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Endocrine Society committees and members and cosponsoring organizations reviewed and commented on preliminary drafts of this guideline. Conclusions: FHA is a form of chronic anovulation, not due to identifiable organic causes, but often associated with stress, weight loss, excessive exercise, or a combination thereof. Investigations should include assessment of systemic and endocrinologic etiologies, as FHA is a diagnosis of exclusion. A multidisciplinary treatment approach is necessary, including medical, dietary, and mental health support. Medical complications include, among others, bone loss and infertility, and appropriate therapies are under debate and investigation.
[Mh] Termos MeSH primário: Amenorreia/diagnóstico
Doenças Hipotalâmicas/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Amenorreia/tratamento farmacológico
Amenorreia/etiologia
Endocrinologia
Medicina Baseada em Evidências
Feminino
Seres Humanos
Doenças Hipotalâmicas/complicações
Doenças Hipotalâmicas/tratamento farmacológico
Medicina Reprodutiva
Sociedades Médicas
Adulto Jovem
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE; JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-00131



página 1 de 833 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde